NEW YORK — September 1, 2026 — One of the most effective acne treatments in dermatology no longer requires a prescription. The FDA approved a fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% for over-the-counter sale in May, for anyone twelve and older, and the product has been reaching major retailers through the summer.
This is a genuine change rather than a repackaging. The combination has been prescribed for more than fifteen years, it is what treatment guidelines recommend as first-line therapy, and it is now sold beside the salicylic acid washes.
Dr. Dennis Porto, a double board-certified dermatologist and Mohs micrographic surgeon, says the access problem this solves has always been larger than the medical one.
“Most acne is not difficult to treat. It is difficult to get treated. A visit, a wait, a prescription, a pharmacy, a copay — that is four places to fall out of the process, and plenty of people fall out at the first one. Removing the whole chain for a first-line therapy matters more than any incremental drug approval this year.”
Why the combination beats either ingredient alone
Acne has several drivers, and these two ingredients address different ones. Adapalene is a retinoid: it normalizes how cells shed inside the follicle, which is what stops pores from plugging in the first place. Benzoyl peroxide is antibacterial and keratolytic, reducing Cutibacterium acnes and helping clear what has already formed.
Used together, they also protect each other's usefulness. Benzoyl peroxide reduces the bacterial resistance that develops when antibiotics are used alone for acne, which is a large part of why guidelines pair it with almost everything.
“A retinoid prevents the next breakout. Benzoyl peroxide treats the one you already have. Patients almost always want the second thing and skip the first, and then wonder why they are still getting new spots. The value of this product is that it takes the choice away — you get both whether you understood the distinction or not.”
What the data actually shows
The OTC approval rested on ten studies across a range of ages, skin tones, and severities. The combination consistently outperformed adapalene alone, benzoyl peroxide alone, and vehicle. Larger trials reported reductions in inflammatory lesions of up to roughly 70% at twelve weeks, with about 65% total lesion reduction sustained at a year.
“Twelve weeks. Not twelve days. Every number worth quoting about this product is measured at three months, and that is the single most important thing for someone buying it to understand before they start.”
The four ways people waste it
Dr. Porto argues that the failures he sees with this combination are almost never pharmacological.
Quitting during the adjustment period. Retinoids commonly cause dryness, redness, and flaking in the first few weeks, and sometimes an initial worsening as existing plugged pores surface. This is expected and temporary. It is also, reliably, when people decide the product is not working.
“Week three is where acne treatment goes to die. Someone is peeling, they have more spots than when they started, and every instinct says stop. If you can explain that in advance, you save the treatment. If nobody explains it, the tube goes in a drawer.”
Using far too much. A pea-sized amount covers the entire face. More does not work faster; it just produces the irritation that causes people to quit. Starting every other night and building to daily is a reasonable approach for anyone with sensitive skin.
Skipping moisturizer. A plain non-comedogenic moisturizer does not reduce efficacy and substantially improves whether someone can tolerate the treatment long enough for it to work.
Ruining the laundry. Benzoyl peroxide bleaches fabric. Towels, pillowcases, shirt collars, and the good sheets are all vulnerable, and nobody mentions it until it has happened.
“Use white towels and a white pillowcase. It sounds like trivial advice next to the pharmacology, and it is the tip patients thank me for most.”
When it is the wrong thing to buy
The risk of moving a treatment to a shelf is that nobody at the shelf is checking the diagnosis.
“Not everything on a face is acne. Perioral dermatitis, rosacea, and fungal folliculitis all get treated as acne by people self-diagnosing in an aisle, and none of them respond to this. If there are no blackheads or whiteheads anywhere, the diagnosis is worth questioning before the treatment is.”
Severity matters as much as diagnosis. This is a first-line product for mild to moderate acne. Deep, painful nodules, cysts, or acne that is already leaving marks and scars is a different problem, and the months spent working through an over-the-counter option are months in which scarring accumulates.
“Scars are the part of acne I cannot undo. I can clear the acne of almost anyone who walks in. I cannot give them back the skin they had before they waited two years. If your acne is leaving marks, that is the signal to stop experimenting and see someone.”
What still requires a prescription
The stronger version of this same combination, adapalene 0.3% with benzoyl peroxide, remains prescription-only, as do the treatments that matter for moderate and severe disease: topical and oral antibiotics, hormonal therapy including spironolactone and combined oral contraceptives, newer topicals such as clascoterone, and isotretinoin.
A reasonable approach is to give the over-the-counter combination a genuine twelve-week trial, used correctly and daily, and to treat that as information rather than a verdict.
“If you have used it properly for three months and you are still breaking out, that is not a failure. That is a useful result, and it tells the next physician you see exactly where to start. Bring the tube and tell them how long you used it. It saves a step.”
Dr. Dennis Porto, MD, MPH, FAAD is a double board-certified dermatologist and Mohs micrographic surgeon, and a Clinical Assistant Professor at Mount Sinai, where he teaches skin cancer surgery to dermatology resident physicians. He treats acne and the other conditions covered by his practice virtually through SkinCare.MD.
Journalists and researchers are welcome to quote from this article. Please attribute quotations to Dennis A. Porto, MD, MPH, FAAD, and cite www.skincare.md as the source. Dr. Porto is available for comment on dermatology and skin cancer topics; interview requests may be directed through the contact information at skincare.md.